CMPS (COMPASS Pathways Plc American Depository Shares)
Insider Trading Activity
Every open-market purchase and sale reported by CMPS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-05 | Kabir Nath | Chief Executive Officer | F | — | — |
| 2026-05-29 | GINO SANTINI | Director | A | — | — |
| 2026-05-29 | Robert McQuade | Director | A | — | — |
| 2026-05-29 | David Y Norton | Director | A | — | — |
| 2026-05-29 | Wayne Joseph Riley | Director | A | — | — |
| 2026-05-29 | Daphne Karydas | Director | A | — | — |
| 2026-05-29 | Justin D. Gover | Director | A | — | — |
| 2026-05-29 | JEFFREY M JONAS | Director | A | — | — |
| 2026-05-29 | Kathleen Tregoning | Director | A | — | — |
| 2026-03-27 | Kabir Nath | Chief Executive Officer | A | — | — |
| 2026-03-27 | Guy Goodwin | Chief Medical Officer | A | — | — |
| 2026-03-27 | Teri Loxam | Chief Financial Officer | A | — | — |
| 2026-03-13 | Teri Loxam | Chief Financial Officer | F | — | — |
| 2026-03-13 | Kabir Nath | Chief Executive Officer | F | — | — |
| 2026-03-03 | Teri Loxam | Chief Financial Officer | F | — | — |
| 2026-02-03 | Kabir Nath | Chief Executive Officer | F | — | — |
| 2025-10-31 | JEFFREY M JONAS | Director | A | — | — |
| 2025-08-04 | Kabir Nath | Chief Executive Officer | F | — | — |
| 2025-07-30 | Justin D. Gover | Director | A | — | — |
| 2025-06-13 | Annalisa Jenkins | Director | A | — | — |
| 2025-06-13 | GINO SANTINI | Director | A | — | — |
| 2025-06-13 | Thomas Lonngren | Director | A | — | — |
| 2025-06-13 | Daphne Karydas | Director | A | — | — |
| 2025-06-13 | Wayne Joseph Riley | Director | A | — | — |
| 2025-06-13 | Robert McQuade | Director | A | — | — |
| 2025-06-13 | David Y Norton | Director | A | — | — |
| 2025-06-13 | Linda McGoldrick | Director | A | — | — |
| 2025-03-13 | Guy Goodwin | Chief Medical Officer | A | — | — |
| 2025-03-13 | Kabir Nath | Chief Executive Officer | A | — | — |
| 2025-03-13 | Teri Loxam | Chief Financial Officer | A | — | — |
| 2025-03-04 | Teri Loxam | Chief Financial Officer | F | — | — |
| 2025-02-05 | Kabir Nath | Chief Executive Officer | F | — | — |
| 2024-10-25 | George Jay Goldsmith | 10%+ Owner | Sell | — | — |
| 2024-10-25 | Ekaterina Malievskaia | 10%+ Owner | Sell | — | — |
| 2024-09-27 | ATAI Life Sciences AG | 10%+ Owner | Sell | — | — |
| 2024-09-04 | GINO SANTINI | Director | A | — | — |
| 2024-08-05 | Kabir Nath | Chief Executive Officer | F | — | — |
| 2024-08-05 | Annalisa Jenkins | Director | F | — | — |
| 2024-05-22 | Ekaterina Malievskaia | 10%+ Owner | Sell | — | — |
| 2024-05-22 | George Jay Goldsmith | 10%+ Owner | Sell | — | — |
| 2024-05-13 | Wayne Joseph Riley | Director | A | — | — |
| 2024-05-13 | Thomas Lonngren | Director | A | — | — |
| 2024-05-13 | Annalisa Jenkins | Director | A | — | — |
| 2024-05-13 | Daphne Karydas | Director | A | — | — |
| 2024-05-13 | Robert McQuade | Director | A | — | — |
| 2024-05-13 | David Y Norton | Director | A | — | — |
| 2024-05-13 | Linda McGoldrick | Director | A | — | — |
| 2024-05-06 | George Jay Goldsmith | 10%+ Owner | Sell | — | — |
| 2024-05-06 | Ekaterina Malievskaia | 10%+ Owner | Sell | — | — |
| 2024-05-03 | Annalisa Jenkins | Director | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 6,905,774 | — |
| — | 10%+ Owner | 6,307,970 | — |
| — | 10%+ Owner | 6,307,970 | — |
| — | Chief Executive Officer | 361,028 | — |
| — | Chief Financial Officer | 152,002 | — |
| — | General Counsel & CLO | 43,340 | — |
| — | Chief Financial Officer | 22,500 | — |
| — | Director | 20,356 | — |
| — | Director | 19,480 | — |
| — | Chief Medical Officer | 8,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CMPS quote page; the site-wide leaderboard is on the insider transactions hub.